Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.…
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems (NASDAQ: DCTH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 156 employees.
The shares were at 18.79 USD on 20 November 2026, up 117.5% over 52 weeks. Its 52-week range is 8.120 USD to 22.51 USD: the price is 16.5% below the high and 131.4% above the low.
At a market capitalisation of 653.67M USD, it trades at 117.4 times trailing earnings and 69.0 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 360% for DCTH.
Delcath Systems reports return on equity of 2.4%, an operating margin of 5.2% and revenue up 70.7% year over year.
It holds more cash than debt, a net cash position of 101.91M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 28.60 USD is 52.2% above the current price. The next earnings report is expected on 25 February 2027.